Adaptimmune Therapeutics (ADAP) Expected to Announce Quarterly Earnings on Tuesday

Adaptimmune Therapeutics (NASDAQ:ADAP) is projected to announce its Q1 2025 earnings results before the market opens on Tuesday, May 13th. Analysts expect Adaptimmune Therapeutics to post earnings of ($0.17) per share and revenue of $6.55 million for the quarter.

Adaptimmune Therapeutics (NASDAQ:ADAP) last announced its earnings results on Monday, March 24th. The biotechnology company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.09). Adaptimmune Therapeutics had a negative return on equity of 74.15% and a negative net margin of 25.43%. The business had revenue of $3.22 million for the quarter, compared to analyst estimates of $16.56 million. On average, analysts expect Adaptimmune Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Adaptimmune Therapeutics Price Performance

Adaptimmune Therapeutics stock opened at $0.29 on Monday. The stock has a market capitalization of $75.27 million, a P/E ratio of -1.33 and a beta of 2.86. The company’s fifty day moving average price is $0.30 and its 200 day moving average price is $0.52. The company has a debt-to-equity ratio of 0.62, a quick ratio of 3.82 and a current ratio of 3.85. Adaptimmune Therapeutics has a 1 year low of $0.20 and a 1 year high of $1.48.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on ADAP shares. Wells Fargo & Company cut their price objective on Adaptimmune Therapeutics from $2.00 to $1.50 and set an “equal weight” rating for the company in a research note on Friday, March 21st. Scotiabank dropped their price target on Adaptimmune Therapeutics from $3.15 to $1.40 and set a “sector outperform” rating for the company in a research report on Friday, March 21st. HC Wainwright reduced their price objective on Adaptimmune Therapeutics from $3.50 to $3.00 and set a “buy” rating for the company in a research note on Tuesday, April 1st. StockNews.com began coverage on shares of Adaptimmune Therapeutics in a research note on Thursday. They set a “buy” rating on the stock. Finally, Jones Trading cut shares of Adaptimmune Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, April 11th. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat, Adaptimmune Therapeutics has an average rating of “Moderate Buy” and an average target price of $1.83.

Adaptimmune Therapeutics Company Profile

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.